R. Ben Taylor's most recent trade in Recursion Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 7,057 Class A Common Stock done at an average price of $4.9 . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.92 per share. | 16 Jun 2025 | 7,057 | 823,134 | - | 4.9 | 34,720 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 15 May 2025 | 11,908 | 830,191 | - | 4.3 | 50,609 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.09 per share. | 01 Apr 2025 | 26,571 | 842,099 | - | 5.1 | 135,379 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.84 per share. | 17 Mar 2025 | 7,057 | 868,670 | - | 6.8 | 48,270 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.64 per share. | 18 Feb 2025 | 10,879 | 875,727 | - | 10.6 | 115,753 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 70,037 | 70,037 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 35,018 | 879,228 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 13,922 | 893,150 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Ben R. Taylor | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.25 per share. | 03 Feb 2025 | 6,544 | 886,606 | - | 7.3 | 47,444 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Taylor R. Ben | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 740,686 | 740,686 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | R. Ben Taylor | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 370,343 | 844,210 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Taylor R. Ben | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 16 Dec 2024 | 15,668 | 480,924 | - | 6.0 | 94,635 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Taylor Ben R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.95 per share. | 16 Dec 2024 | 7,057 | 473,867 | - | 6.9 | 49,046 | Class A Common Stock |